Caenorhabditis elegans: A versatile platform for drug discovery
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Drug discovery and drug target identification are two intimately linked facets of intervention strategies aimed at effectively combating pathological conditions in humans. Simple model organisms provide attractive platforms for devising and streamlining efficient drug discovery and drug target identification methodologies. The nematode worm Caenorhabditis elegans has emerged as a particularly convenient and versatile tool that can be exploited to achieve these goals. Although C. elegans is a relatively modern addition to the arsenal of model organisms, its biology has already been investigated to an exceptional level. This, coupled with effortless handling and a notable low cost of cultivation and maintenance, allows seamless implementation of high‐throughput drug screening approaches as well as in‐depth genetic and biochemical studies of the molecular pathways targeted by specific drugs. In this review, we introduce C. elegans as a model organism with significant advantages toward the identification of molecular drug targets. In addition, we discuss the value of the worm in the development of drug screening and drug evaluation protocols. The unique features of C. elegans, which greatly facilitate drug studies, hold promise for both deciphering disease pathogenesis and formulating educated and effective therapeutic interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The embryonic cell lineage of the nematode Caenorhabditis elegans
Sulston, J. E., Schierenberg, E., White, J. G., & Thomson, J. N. (1983) · Developmental Biology · doi:10.1016/0012-1606(83)90201-4 · Cited by 4,199
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 1×
“These include metabolic disorders such as obesity and diabetes [11, 45], neurodegenerative disorders, including Alzheimer’s [46–48], Parkinson’s [49] and Huntington’s [50] diseases, depression [18, 20], cancer [51], and other genetic diseases such as autosomal dominant polycystic kidney disease (ADPKD; [52]), muscular…”
BackgroundThe plasticity of aging: insights from long-lived mutants
Kenyon, C. (2005) · Cell · doi:10.1016/j.cell.2005.02.002 · Cited by 1,338 · cited 1×
“elegans has contributed enormously to our understanding of human neurodegenerative disorders [2], cancer [3], and aging [4].”
BackgroundA systematic RNAi screen identifies a critical role for mitochondria in C. elegans longevity
Lee, S. S., Lee, R. Y. N., Fraser, A. G., Kamath, R. S., Ahringer, J., & Ruvkun, G. (2003) · Nature Genetics · doi:10.1038/ng1056 · Cited by 969 · cited 1×
“elegans genome are available [12] and have proven powerful tools toward unraveling genes implicated in particular biological processes such as development [34, 35], fat storage [11], and longevity [36].”
BackgroundThe structure of the ventral nerve cord of Caenorhabditis elegans
White, J. G., Southgate, E., Thomson, J. N., & Brenner, S. (1976) · Philosophical Transactions of the Royal Society of London. B, Biological Sciences · doi:10.1098/rstb.1976.0086 · Cited by 616 · cited 1×
“KGaA, Weinheim neurons and their connecting synapses has been elucidated from serial section electron micrographs [6].”
BackgroundA polycystic kidney-disease gene homologue required for male mating behaviour in C. elegans
Barr, M. M., & Sternberg, P. W. (1999) · Nature · doi:10.1038/43913 · Cited by 541 · cited 1×
“These include metabolic disorders such as obesity and diabetes [11, 45], neurodegenerative disorders, including Alzheimer’s [46–48], Parkinson’s [49] and Huntington’s [50] diseases, depression [18, 20], cancer [51], and other genetic diseases such as autosomal dominant polycystic kidney disease (ADPKD; [52]), muscular…”
BackgroundNollen, E. A. A., Garcia, S. M., van Haaften, G., Kim, S., Chavez, A., Morimoto, R. I., & Plasterk, R. H. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307697101 · Cited by 416 · cited 2×
“Others, such as the Huntington’s disease model, have been used in the academic world in genome-wide RNAi screens to identify regulators of polyglutamine aggregation [56].”
Cited by
Alternatives to animal testing: a review
Doke, S. K., & Dhawale, S. C. (2015) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.11.002 · Cited by 564
High‐throughput screening and small animal models, where are we?
Giacomotto, J., & Ségalat, L. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00725.x · Cited by 293
Ramot, D., Johnson, B. E., Berry, T. L., Carnell, L., & Goodman, M. B. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002208 · Cited by 278
C. elegans in high-throughput drug discovery
O'Reilly, L. P., Luke, C. J., Perlmutter, D. H., Silverman, G. A., & Pak, S. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.12.001 · Cited by 267
An image analysis toolbox for high-throughput C. elegans assays
Wählby, C., Kamentsky, L., Liu, Z. H., Riklin-Raviv, T., Conery, A. L., O'Rourke, E. J., Sokolnicki, K. L., Visvikis, O., Ljosa, V., Irazoqui, J. E., et al. (2012) · Nature Methods · doi:10.1038/nmeth.1984 · Cited by 181
Laser-induced vapour nanobubbles improve drug diffusion and efficiency in bacterial biofilms
Teirlinck, E., Xiong, R., Brans, T., Forier, K., Fraire, J., Van Acker, H., Matthijs, N., De Rycke, R., De Smedt, S. C., Coenye, T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06884-w · Cited by 154
C. elegans as a model organism for human mitochondrial associated disorders
Maglioni, S., & Ventura, N. (2016) · Mitochondrion · doi:10.1016/j.mito.2016.02.003 · Cited by 54
Metadata
- Authors
- Artal‐Sanz, M., de Jong, L., & Tavernarakis, N.
- Venue
- Biotechnology Journal
- Publisher
- Wiley
- Published
- 2006-12
- Volume
- 1
- Issue
- 12
- Pages
- 1405-1418
- ISSN
- 1860-6768 (ISSN-L)
- 1860-7314
- OpenAlex
- W2115010963
- Cited by
- 153
- References
- 7
- FWCI
- 4.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.